Back to Journals » OncoTargets and Therapy » Volume 12

Selecting treatment options in refractory metastatic colorectal cancer

Authors Byrne M, Saif MW

Received 14 November 2018

Accepted for publication 13 February 2019

Published 27 March 2019 Volume 2019:12 Pages 2271—2278

DOI https://doi.org/10.2147/OTT.S194605

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Gaetano Romano


Margaret Byrne, Muhammad Wasif Saif

Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USA

Abstract: Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.

Keywords: TKI, fluoropyrimidine, bevacizumab, cetuximab, panitumumab, PD-1 inhibitor, FOLFIRI, epidermal growth factor receptor, vascular endothelial growth factor receptor, platelet-derived growth factor receptors, KRAS, NRAS, HER2, advanced, colon cancer, refractory, Lonsurf, regorafenib


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]